Network pharmacology-based identification of potential drug targets and bioactive compounds in Lycii Fructus (Gouqizi) for the therapeutics of Parkinson’s disease

RMSD analysis of the top docked complexes showed that AKT1 - 24-ethylcholesta-5,22-dienol and MAOB-24-ethylcsecrholesta-5,22-dienol remained stable, whereas 4alpha-methyl-24-ethylcholesta-7,24-dienol exhibited fluctuations with TNF over 100 nanoseconds. These findings indicate that <i>Lycii Fructus</i> extracted compounds have high potential for targeting PD targets; further <i>in vitro</i> and <i>in vivo</i> experiments are necessary to assess their effectiveness in managing PD progression.